Relmada Therapeutics, Inc. (RLMD)

7.66 +0.14 (+1.86%) USD  |  NASDAQ  |  May 01, 16:00
7.49 -0.17 (-2.22%) After-Hours: 19:46
More

Relmada Therapeutics Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for RLMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Catalyst Pharmaceuticals, Inc. Upgrade
Theravance Biopharma, Inc. Upgrade
Avalo Therapeutics, Inc. Upgrade
AN2 Therapeutics, Inc. --
ACADIA Pharmaceuticals, Inc. Upgrade